OYST - 3 Top Pharma Stocks to Buy Right Now
Developing novel drugs for unmet medical needs remains the mission for many emerging drug developers. These pharma companies tackle a range of diseases but have one common attribute. Healthcare investors can look past the development risk. Two companies have approved drugs recently launched into the market, and the third aims to join those ranks next year.
Global Blood Therapeutics (NASDAQ: GBT) crushed analyst estimates when it reported its first-quarter results on May 6. In its first full quarter on the market, Global Blood's sickle cell disease drug Oxbryta posted $14.1 million in net sales. That's several-fold higher than the $2.2 million to $5.5 million in sales predicted by Wall Street analysts.
Image source: Getty Images.